syahrir maulana/iStock by way of Getty Pictures
Shares of Axsome Therapeutics (NASDAQ: NASDAQ:AXSM) fell on Monday following the U.S. FDA’s resolution to not evaluate the advertising software for esreboxetine or AXS-14, for the remedy of fibromyalgia.
The FDA stated that after an preliminary evaluation, the New Drug Utility
